A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01143246 |
Recruitment Status :
Completed
First Posted : June 14, 2010
Last Update Posted : September 23, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HRS | Drug: Terlipressin Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 196 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) |
Study Start Date : | September 2010 |
Actual Primary Completion Date : | February 2013 |
Actual Study Completion Date : | May 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Terlipressin
intravenous terlipressin (1 mg) every 6 hours with concomitant albumin
|
Drug: Terlipressin
Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
Other Name: Lucassin® |
Placebo Comparator: Placebo
lyophilized mannitol
|
Drug: Placebo
Lyophilized mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
Other Name: Saline |
- Confirmed Hepatorenal syndrome reversal [ Time Frame: Baseline and 14 days ]Confirmed HRS Reversal: The percentage of subjects with two serum creatinine (SCr) values of ≤ 1.5 mg/dL at least 48 hours apart, on treatment, and without intervening RRT or liver transplant.
- Hepatorenal syndrome reversal [ Time Frame: 14 days ]Incidence of HRS Reversal is defined as at least one SCr value of ≤ 1.5 mg/dL on treatment (up to 24 hours after the last dose of study medication).
- Transplant-free survival [ Time Frame: Up to 90 days ]Transplant-Free Survival up to 90 days, defined as the time (in days) that each subject survives without liver transplantation from the day of randomization.
- Overall Survival [ Time Frame: Up to 90 days ]Overall Survival up to 90 days, defined as the time (in days) that each subject survives from the day of randomization.
- Serious Adverse Events [ Time Frame: Up to 30 days post treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent by subject or legally authorized representative
- At least 18 years of age
- Cirrhosis and ascites
-
Rapidly progressive reduction in renal function characterized by:
- SCr ≥ 2.5 mg/dL
- Doubling of SCr within 2 weeks (or for observations of shorter duration, SCr values over time meeting slope-based criteria for proportional increases likely to be representative of at least a doubling within 2 weeks
- No sustained improvement in renal function (< 20% decrease in SCr and SCr ≥ 2.25 mg/dL) 48 hours after both diuretic withdrawal and the beginning of plasma volume expansion with albumin:
Note: Albumin doses recommended by the IAC are 1 g/kg on the first day (Maximum 100 g) and 20 - 40 g/day thereafter as clinically indicated.It is recommended (if clinically appropriate) that the albumin dose is kept constant during the study drug administration period.
Note: The qualifying SCr value is the SCr value at least 48 hrs after both diuretic withdrawal (if applicable) and the beginning of albumin fluid challenge. The qualifying SCr value must be ≥ 2.25 mg/dL AND at least 80% of the diagnostic (pre-fluid challenge) SCr value.
Exclusion Criteria:
- Serum creatinine > 7 mg/dL
- Shock Note: Hypotension (Mean Arterial Pressure < 70 mm Hg or a decrease > 40 mm Hg in systolic blood pressure from baseline) with evidence of hypoperfusion abnormalities despite adequate fluid resuscitation.
-
Sepsis or systemic inflammatory response syndrome (SIRS)
Note: SIRS: Presence of 2 or more of the following findings:
Temperature > 38°C or < 36°C; heart rate > 90/min; respiratory rate of > 20/min or a PaCO2 of < 32 mm Hg; white blood cell count of > 12,000 cells/µL or < 4,000/ µL.
Note: Sepsis: Documented infection and systemic inflammatory response syndrome.
- < 2 days anti-infective therapy for documented or suspected infection
- Proteinuria > 500 mg/day
- Hematuria or microhematuria (> 50 red blood cells per high power field)
-
Clinically significant casts on urinalysis, including granular casts
Note: Urine sediment examination is required to exclude presence of granular casts and other clinically significant casts (e.g., red blood cell [RBC] casts).
- Evidence of intrinsic or parenchymal renal disease (including acute tubular necrosis)
- Obstructive uropathy or other renal pathology on ultrasound or other medical imaging
- Current or recent treatment (within 4 weeks) with nephrotoxic drugs, e.g., aminoglycosides, nonsteroidal anti-inflammatory drugs (NSAID) Note: Up to 3 doses of an NSAID within the prior month (prescription or over the counter) is acceptable Note: Use of short-term (< 2 weeks) oral neomycin for acute encephalopathy is acceptable.
- Current or recent (within 4 weeks) renal replacement therapy
- Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning)
- Current or recent treatment (within 48 hours) with octreotide, midodrine, vasopressin, dopamine or other vasopressors
- Severe cardiovascular disease as judged by investigator
- Estimated life expectancy of less than 3 days
- Confirmed pregnancy
- Known allergy or sensitivity to terlipressin or another component of the study treatment
- Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01143246

Study Director: | Khurram Jamil, MD | Mallinckrodt |
Responsible Party: | Mallinckrodt |
ClinicalTrials.gov Identifier: | NCT01143246 |
Other Study ID Numbers: |
IK-4001-HRS-301 |
First Posted: | June 14, 2010 Key Record Dates |
Last Update Posted: | September 23, 2016 |
Last Verified: | September 2016 |
Hepatorenal syndrome Renal failure Cirrhosis Alcoholic hepatitis Ascites |
Hepatorenal Syndrome Liver Diseases Digestive System Diseases Kidney Diseases |
Urologic Diseases Terlipressin Antihypertensive Agents Vasoconstrictor Agents |